Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004
CompanyDeals

Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China
CompanyDeals

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D
CompanyDeals

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D

Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition
Company

Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
CompanyDrug

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma

Junshi Biosciences' Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
CompanyDrug

Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment

Shandong Boan's Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
CompanyDrug

Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment

Boehringer Ingelheim's HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
CompanyDrug

Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets
CompanyDeals

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets

Tigermed Partners with Africare BioPharma to Enhance Africa's Clinical Research Capabilities
CompanyDeals

Tigermed Partners with Africare BioPharma to Enhance Africa’s Clinical Research Capabilities

Johnson & Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment
CompanyDrug

Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors
CompanyDrug

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors